An observational study in Patients That Have Been Diagnosed With Colorectal Cancer and Patients Eligible for Tumor Biopsy, sponsored by Fore Biotherapeutics. Completed at 1 site in Israel. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-03-29.
Sponsored by Fore Biotherapeutics · Observational
NovellusDx is developing a diagnostic platform for the personalized cancer therapy based on patient derived tumor tissue. The assay is able to sense activating mutations by monitoring their effect on a chip-based device.
Patients that have been diagnosed with cancer and are eligible for tumor biopsy will be enrolled.
Exclusion Criteria:
Correct identification of tumor mutant genes
Correct identification of tumor mutant genes, in over 85% of the cases
Time frame: up to 12 month
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fore Biotherapeutics